A monkeypox mRNA-lipid nanoparticle vaccine targeting virus binding, entry, and transmission drives protection against lethal orthopoxviral challenge
A. W. Freyn, C. Atyeo, P. L. Earl, J. L. Americo, G.-Y. Chuang, H. Natarajan, T. R. Frey, J. Gall, J. I. Moliva, R. Hunegnaw, G. Asthagiri Arunkumar, C. Ogega, A. Nasir, H. Bennett, J. Johnson, , B. Moss
This paper develops an mRNA-lipid nanoparticle vaccine targeting four conserved MPXV surface proteins, showing superior protection against VACV compared to MVA.
bioRxiv · Dec 17, 2022 · PreprintImmunology